Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07161037 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Study acronym: AGLOW
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fields
  2. Eligibility criteria expanded, about 7 words Site details revised at 4 of 43 sites · Publications: details revised at 1 of 1 entry Show 2 more changesShow less
    • Site details revised at 4 of 43 sites
    • Publications: details revised at 1 of 1 entry
  3. Re-verified, no change to tracked fieldsv17
  4. Enrollment closed, study ongoing Enrollment target: estimated 24 to confirmed 26 · Site details revised at 43 of 43 sitesv16 Show 2 more changesShow less
    • Enrollment target: estimated 24 to confirmed 26
    • Site details revised at 43 of 43 sites
  5. Study sites: 42 to 43v15
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 40 to 42v14
  2. Study sites: 38 to 40v13
  1. Trial sites expanded: 35 → 38 locationsv12
  2. Study sites: 34 to 35v11
  3. Study sites: 33 to 34v10
  4. Study sites: 30 to 33v9
  5. Study sites: 29 to 30v8
  6. Study sites: 25 to 29v7
  7. Study sites: 21 to 25v6
  8. Study sites: 11 to 21v5
  9. Study sites: 5 to 11 Start date changed from estimate of Oct 23, 2025 to Nov 19, 2025 · Study title expanded, about 1 wordv4 Show 2 more changesShow less
    • Start date changed from estimate of Oct 23, 2025 to Nov 19, 2025
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  10. Study sites: 4 to 5 Start date: Sep 26, 2025 to Oct 23, 2025v3 Show 1 more changeShow less
    • Start date: Sep 26, 2025 to Oct 23, 2025
  11. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 4v2 Show 1 more changeShow less
    • Study sites: 0 to 4
  12. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
Trial Details
NCT Number NCT07161037
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov